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Cardiac T1 Mapping and Extracellular
Volume (ECV) in clinical practice: a
comprehensive review
Philip Haaf1,2*, Pankaj Garg1, Daniel R. Messroghli3, David A. Broadbent1, John P. Greenwood1 and Sven Plein1*
Abstract
Cardiovascular Magnetic Resonance is increasingly used to differentiate the aetiology of cardiomyopathies. Late
Gadolinium Enhancement (LGE) is the reference standard for non-invasive imaging of myocardial scar and focal
fibrosis and is valuable in the differential diagnosis of ischaemic versus non-ischaemic cardiomyopathy. Diffuse
fibrosis may go undetected on LGE imaging. Tissue characterisation with parametric mapping methods has the
potential to detect and quantify both focal and diffuse alterations in myocardial structure not assessable by LGE.
Native and post-contrast T1 mapping in particular has shown promise as a novel biomarker to support diagnostic,
therapeutic and prognostic decision making in ischaemic and non-ischaemic cardiomyopathies as well as in
patients with acute chest pain syndromes. Furthermore, changes in the myocardium over time may be assessed
longitudinally with this non-invasive tissue characterisation method.
Keywords: T1 mapping, ECV, Cardiomyopathy, Acute chest pain syndromes, Diffuse myocardial fibrosis
Background
Cardiovascular Magnetic Resonance (CMR) is increas-
ingly used to differentiate the aetiology of cardiomyopa-
thies. Its three-dimensional nature with excellent spatial
resolution and high tissue contrast enables accurate
measurement of cardiac function and morphology: left
ventricular volumes, mass and ejection fraction as well
as an assessment of regional wall motion abnormalities
can be achieved largely independent of body habitus,
imaging windows and without ionising radiation expos-
ure [1]. Recent advances in CMR provide the potential
to also assess and quantify myocardial tissue composition
[2]. This article aims to review and illustrate advances in
parametric mapping methods, in particular T1 mapping
in cardiac diseases and to appraise their clinical potential
in the context of established CMR methods.
Late gadolinium enhancement
Late Gadolinium Enhancement (LGE) has become the ref-
erence standard for non-invasive imaging of myocardial
scar and focal fibrosis in both ischaemic [3] and non-
ischaemic cardiomyopathy [4]. LGE imaging depicts the
relative difference in longitudinal recovery times (T1)
between enhancing areas of fibrosis or scar (T1 shortened
due to accumulation of extracellular gadolinium contrast
agent) and normal nulled myocardium (longer T1 as
gadolinium contrast agent is more rapidly washed out)
[2]. The method has particular value in the differential
diagnosis of ischaemic versus non-ischaemic cardiomyop-
athy based on the location and transmural extent of
scar. Based upon specific LGE patterns some of the non-
ischaemic cardiomyopathies can be further differentiated.
Diffuse fibrosis can go undetected on LGE imaging
because of the absence of normal reference myocardium
and the identification of microscopic interstitial fibrosis is
limited by the spatial resolution of LGE images. In the set-
ting of diffuse fibrosis, presence of LGE has been shown
to correlate poorly with collagen volume calculated from
endomyocardial biopsies [2]. Although numerous quantifi-
cation methods for LGE exist, the presence of fibrosis and
scarring is generally identified qualitatively by visual inter-
pretation of LGE images, limiting the ability to compare
findings between subjects or in follow-up examinations.
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Principles of T1 mapping
T1 mapping measures the longitudinal or spin-lattice re-
laxation time, which is determined by how rapidly pro-
tons re-equilibrate their spins after being excited by a
radiofrequency pulse. In 1970, Look and Locker pro-
posed methods to measure T1 relaxation times by ac-
quiring data successively after magnetisation inversion
[5]. Subsequently, these methods have been refined and
acquisition times shortened. The Modified Look-Locker
Inversion recovery (MOLLI) pulse sequence allows
measurement of T1 times in a single breath hold over
17 successive heart beats and has become the most
popular T1 mapping method [6]. The main difference
between conventional Look-Locker and MOLLI is that
in the latter the images are acquired at the same cardiac
phase allowing mapping. Variations of MOLLI have been
proposed allowing shortened breath-hold durations and
reduced sensitivity to heart rate, such as the 5(3)3
scheme indicated in Fig. 1. The Shortened MOLLI
(ShMOLLI) scheme uses sequential inversion-recovery
measurements with a single breath hold of only nine suc-
cessive heart beats [7] and a conditional fitting algorithm
to account for the short recovery period between inver-
sion pulses. Other pulse sequences including saturation
recovery single-shot acquisition (SASHA) [8] and satur-
ation pulse prepared heart-rate-independent inversion re-
covery (SAPPHIRE) [9] are also used in clinical practice.
T1 mapping refers to pixelwise illustrations of absolute
T1 relaxation times on a map. T1 mapping circumvents
the influence of windowing and nulling (as in LGE) and
allows direct T1 quantification. As such, T1 mapping
has the potential to detect diffuse myocardial structural
alterations not assessable by other non-invasive means,
including LGE.
Currently used T1 mapping methods acquire a set of
non-segmented raw images within separate cardiac cy-
cles of a single breath-hold. As a result, the acquisition
duration for each raw image is limited to approximately
200 ms within the cardiac cycle, which limits the spatial
resolution that can be achieved. In addition, poor
breath-holding can significantly impair the quality of T1
maps, which can be compensated for to some extent by
the application of manual or automatic motion correc-
tion. The differences in acquisition schemes have a direct ef-
fect on the range of normal and abnormal T1 with a given
technique [10], which means that absolute T1 values can
only be directly compared when they were obtained with
the same acquisition scheme at the same field strength using
the same post-processing methods. Thus, reports on T1
values should always include the T1 mapping technique that
was used and the site-specific normal range for T1 [11]. Mo-
tion correction is essential for high quality T1 mapping and
is generally achieved with breath holding. Image quality can
be improved with respiratory motion compensation
methods in patients with poor breath-holding [12] and
phase sensitive inversion recovery reconstruction [13] fur-
ther improved image quality. Nevertheless, residual uncor-
rected respiratory motion is still problematic particularly if
unrecognized and in areas of thin myocardium [14].
Native T1 mapping
Native T1 values are primarily influenced by the field
strength used, with higher native T1 values at 3 T than at
1.5 T [15]. Measured T1 values also depend on the pulse
Fig. 1 Modified Look-Locker Inversion Recovery (MOLLI) scheme for T1-mapping in the heart. This protocol employs two inversions to acquire eight
images over 11 heart beats, referred to here as 5(3)3, which means five images are acquired over consecutive cardiac cycles followed by a three heart
beat gap and then three images are acquired over consecutive cardiac cycles. 5s(3s)3s MOLLI schemes would acquire images for a duration of 5s
followed by a gap of 3s and a second acquisition train lasting 3s, further minimizing heart rate dependency of the results. For illustrative purpose, the
orange arrow and relaxation curve refer to an area of myocardial infarction and elevated native T1 values. The green arrow and relaxation curve refer to
an area of normal septal myocardium and normal native T1 values. Images are sorted by inversion times
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sequence used (MOLLI and ShMOLLI generally under-
estimate T1), the cardiac phase (diastole versus systole)
and region of measurement [15]. Normal native T1 values
are thus specific to the local set-up [16] and need to be
reassessed when the acquisition method is changed. Any
of the currently used pulse sequence schemes have dem-
onstrated very high inter-study reproducibility for native
myocardial T1.
The two most important biological determinants of an
increase in native T1 are oedema (increase of tissue water
in e.g. acute infarction of inflammation) and increase of
interstitial space (e.g. fibrosis of infarction (scar) or cardio-
myopathy, and in amyloid deposition). The two most im-
portant determinants of low native T1 values are lipid
overload (e.g. Anderson-Fabry disease, lipomatous meta-
plasia in chronic myocardial infarction) and iron overload.
Native T1 values are a composite signal of myocytes and
extracellular volume (ECV) with the potential of pseudo-
normalization of abnormal values (e.g. low native T1
values of Anderson-Fabry disease cancelled out by infero-
lateral fibrosis). Native T1 mapping is feasible even in pa-
tients with severe renal impairment in whom gadolinium-
based contrast agents are contraindicated.
Contrast-enhanced T1 Mapping and Extracellular
Volume (ECV) fraction
Contrast-enhanced T1 mapping is used for mostly calcu-
lating the ECV fraction in combination with native T1
mapping. Standard gadolinium-based contrast agents are
distributed throughout the extracellular space and
shorten T1 relaxation times of myocardium proportional
to the local concentration of gadolinium [2]. Areas of fi-
brosis and scar will therefore exhibit shorter T1 relax-
ation times, in particular after contrast administration.
The haematocrit represents the cellular fraction of
blood. Estimation of the ECV (interstitium and extracel-
lular matrix) requires measurement of myocardial and
blood T1 before and after administration of contrast
agents as well as the patient’s haematocrit value accord-
ing to the formula:
ECV ¼ 1−haematocritð Þ
1
post contrast T1 myo
−
1
native T1 myo
1
post contrast T1 blood
−
1
native T1 blood
ECV is a marker of myocardial tissue remodelling and
provides a physiologically intuitive unit of measurement.
Normal ECV values of 25.3 ± 3.5% [1.5 T] have been re-
ported in healthy individuals [17] (Fig. 2). Apart from
amyloid, an increased ECV is most often due to exces-
sive collagen deposition and is thus a more robust meas-
ure of myocardial fibrosis. Low ECV values occur in
thrombus and fat/lipomatous metaplasia. ECV can ei-
ther be calculated for myocardial regions-of-interest or
visualized on ECV maps.
Unlike native T1 relaxation times, contrast-enhanced
T1 values are more variable and dependent on contrast
Fig. 2 Tissue characterisation using native T1 and extracellular volume fraction (ECV). Absolute values for native T1 depend greatly on field
strength (1.5 T or 3 T), pulse sequence (MOLLI or ShMOLLI), scanner manufacturer and rules of measurements. For the purpose of comparability,
only studies using 1.5 T scanners were considered in this figure. Figure adapted from Martin Ugander (SCMR 2014)
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agent dosing, the time elapsed between contrast
agent administration and T1 measurement and renal
clearance. ECV on the other hand represents a
physiological parameter and is derived from the ratio
of T1 signal values. ECV values may therefore be
more reproducible between different field strengths,
vendors and acquisition techniques than both native
and post-contrast T1 [11]. ECV measures also ex-
hibit better agreement with histological measures of
the collagen volume fraction than isolated post-
contrast T1 [18].
Clinical use of T1 mapping and ECV
Acute chest pain syndromes
Native T1 and ECV help in the differential diagnosis of
patients with acute chest pain including acute coronary
syndrome, myocarditis and Takotsubo cardiomyopathy
and can help in the distinction of acute from chronic in-
farction (Fig. 3).
Acute myocarditis
Endomyocardial biopsy is still the gold standard for
confirmation of myocarditis but remains limited by
frequent sampling errors reducing diagnostic yield
and its invasiveness. In clinical practice, clinical his-
tory, laboratory analyses and imaging findings are
therefore generally used to diagnose acute myocardi-
tis. The “Lake-Louise” CMR [19] criteria have been
widely used to diagnose myocarditis: the diagnosis is
likely if two of the three criteria myocardial oedema
(T2-weighted imaging), LGE in a mid-wall non-
coronary pattern often in the infero-lateral wall, and
hyperaemia/capillary leak (increased early gadolin-
ium enhancement ratio between myocardium and
skeletal muscle) are present. Radunski et al. have
performed a comprehensive comparison of the diag-
nostic accuracy of conventional CMR techniques and
novel mapping techniques and demonstrated better
diagnostic accuracy of T1 mapping and in particular
by ECV [20] (Fig. 4a). Both T1 and ECV mapping
allow for more sensitive identification and quantifi-
cation of diffuse myocardial fibrosis and oedema
than LGE. LGE together with ECV quantification
(ECV ≥27% as diagnostic criterion) significantly im-
proved the diagnostic accuracy to 90% (95% CI: 84–
95%) compared with 79% (95% CI: 71–85%; p =
0.0043) for the “Lake-Louise” CMR criteria [19]. In
patients with severe myocarditis (new-onset heart
failure or acute chest pain) raised native T1 (1098 ±
41 ms [1.5T]) and ECV (31 ± 3% [1.5T]) have been
reported [20] (Fig. 2). High diagnostic performance
(~90% overall sensitivity, specificity and diagnostic
accuracy) has been reported for detecting changes in
myocarditis using an absolute T1 cut-off of 990 ms
[21]. The cut-off value proposed in this study is
however specific to the field strength, vendor and T1
Fig. 3 Acute chest pain syndromes algorithm using multi-parametric tissue characterisation. ECV denotes extra-cellular volume, LGE Late Gadolinium
Enhancement, and MVO microvascular obstruction. . *This holds true for classical type 1 Takotsubo Cardiomyopathy
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mapping technique used and cannot be universally
applied.
Takotsubo cardiomyopathy
Acute but rapidly reversible mid and apical left ventricu-
lar (LV) segment akinesia with ballooning and compen-
satory hyperkinesia of basal segments is the typical
finding in Takotsubo or stress-induced cardiomyopathy.
Typically there are no perfusion defects and no scar on
LGE imaging in contrast to myocarditis and myocardial
infarction. In current clinical practice, T2-weighted
imaging using the short-tau inversion recovery (STIR)
sequence is used to detect oedema. T1 mapping has
potential advantages over T2 STIR as it is a quantitative
Fig. 4 Multi-parametric tissue characterisation at mid-slice in acute chest pain syndromes. On ECV-maps, red areas represent ECV greater than
30%. T1-mapping was done using a modified Look-Locker Inversion Recovery (MOLLI) pulse sequence on 1.5 Tesla Ingenia, Philips, Best, The
Netherlands. a Acute myocarditis with higher native T1-values in the infero-lateral wall of the left ventricle (a1) consistent with LGE in the mid
inferior-lateral wall (a2, yellow arrow). The ECV map (a3) demonstrates diffusely increased extra-cellular space. b Takotsubo Cardiomyopathy (TC)
with diffusely high native T1 values (b1), no evidence of focal LGE (b2) and diffusely increased ECV (b3). c Acute re-perfused ST-elevation myocardial
infarction affecting the inferior wall. Native T1-vales are raised in the area of risk (>1000ms) and also in the remote myocardium. On LGE imaging,
inferior infarction with an area of microvascular obstruction can be seen (yellow arrow, c2). ECV is raised in the infarct zone but low in the MVO as this
area does not take up any contract (yellow arrow, c3). d Anterior wall ST-elevation myocardial infarction with rupture of the left ventricle
free wall (not seen in these images) resulting in haemo-pericardium. The pericardial haemorrhage has high native T1 values (black arrow,
d1), high signal on LGE and low ECV values (d3). e Chronic MI in the antero-septal wall. There is an area of reduced native T1 values in
the septum (green arrow, e1) which corresponds to lipomatous metaplasia transformation in previous antero-septal infarct. There is also
an acute infarction in the lateral wall with some peri-infarct oedema seen on native T1. Abbreviations: AMI, acute myocardial infarction;
ECV, extra-cellular volume; MI, myocardial infarction; LGE, Late Gadolinium Enhancement; TC, Takotsubo Cardiomyopathy
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method that is not in need of a reference region of inter-
est (ROI) and it can be obtained in a single breath hold.
Ferreira et al. demonstrated elevated native T1 values
with a good correlation between T1 values and T2 signal
intensity (SI) ratios and high diagnostic accuracy (AUC
= 0.94, sensitivity and specificity of 92%) in the differen-
tiation between oedema and normal myocardium [22]
(Figs. 2 and 4b). Elevated native T1 values can both be
caused by myocardial oedema and fibrosis. In clinical
practice, a presumable myocardial oedema zone in
Takotsubo cardiomyopathy might be further substanti-
ated with T2-weighted imaging such as STIR sequences
or T2 mapping sequences. The presence of fibrosis, as
may exist if the patient has another underlying path-
ology, may cause an increased ECV.
Acute myocardial infarction
Ischaemia triggers the development of cellular oedema.
Native T1 reliably detects segmental abnormalities
caused by acute myocardial infarction (MI) with high
sensitivity and specificity [23]. T1 mapping detects myo-
cardial oedema in both ST-elevation MI (STEMI) and
non ST-elevation MI (NSTEMI) patients [24] and is at
least as sensitive as T2-STIR [22], in particular in pa-
tients with smaller infarcts [23] (Fig. 4c, d). Although
the distinction of acute vs. chronic MI can be chal-
lenging, T1 values in acute MI are generally higher
than in chronic MI and thus may allow distinction of
an acute coronary syndrome (ACS) from chronic in-
jury. Prescribing a distinct cut-off value that can be
used in an individual patient is hampered by the gen-
eral variability of native T1 values between subjects,
the influence of field strength and acquisition pulse
sequence on T1 values and the influence of infarct
size on T1 values. In practice, the distinction of acute
vs. chronic MI remains mainly based on the overall
assessment of infarct, oedema (area at risk), and
microvascular obstruction zone.
Furthermore, T1 values progress from normal myocar-
dium to that of maximal injury and can be used for de-
fining the peri-infarct zone/area-at-risk [24]. The
longitudinal relaxation time measured by T1 mapping is
mainly related to tissue fibrosis and oedema. Carrick et
al. [25] have shown that an infarct core with native T1
values lower than the surrounding area at risk correlated
with the microvascular obstruction zone by contrast-
enhanced CMR and was associated with worse clinical
outcome.
A recent study of 300 patients with reperfused STEMI
demonstrated native T1 remote from infarcted myocar-
dium at baseline to be independently predictive of
adverse LV remodelling and adverse cardiac events 6
months post-STEMI [26]. Native T1 values in acute MI
are high and ECV values are among the highest of all
cardiac disease (58.5 ± 7.6) [17], most likely due to dis-
ruption of cardiomyocyte membrane integrity and subse-
quent expansion of the distribution volume of
extracellular contrast agents (Fig. 2).
Microvascular obstruction in the infarct core (no-re-
flow phenomenon) results in a pseudo-normalization of
T1 values in this area [23, 24]. Due to accumulation of
methaemoglobin (T1 shortening effect), T1 can even be
decreased in the case of intramyocardial haemorrhage
(Fig. 4c).
Native T1 mapping might also be useful in the assess-
ment of complication of AMI as illustrated in Fig. 4d
showing haemo-pericardium with high native T1 values
in a patient with ruptured LV free wall.
Chronic myocardial infarction
In chronic MI, the necrotic and oedematous infarct tis-
sue of an acute infarct is replaced by a smaller area of
increased extracellular collagen (fibrous scar). Native T1
values are therefore lower and less extensive in chronic
MI compared with the acute stage. The ECV of chronic-
ally infarcted myocardium has been shown to be mark-
edly elevated (51 ± 8%) compared to normal
myocardium but slightly lower than in acutely infarcted
myocardium (Figs. 2 and 4e) [27].
T1 mapping is also able to illustrate areas of lipoma-
tous metaplasia in chronic MI, the presence of which al-
ters the electrical properties of the myocardium and
might play a role in post-MI arrhythmogenesis [28]. Fat
has very low T1 values (230–350 ms at 1.5 T) [29] and
the fatty replacement area within the infarct core there-
fore displays noticeable T1 decrease [24].
Non-ischaemic cardiomyopathies
Cardiac amyloidosis
Amyloidosis can be regarded as the exemplar of an
interstitial disease. Although endomyocardial biopsy re-
mains the reference standard for diagnosis, it is not rou-
tinely performed because it is invasive and prone to
sampling errors with false-negative results. The typical
constellation on echocardiography (concentric LV hyper-
trophy, bi-atrial dilatation, restrictive filling), ECG (low-
voltage QRS in spite of LV hypertrophy) and elevated
blood biomarkers (cardiac troponin and natriuretic pep-
tides) is found mainly in advanced disease. Myocardial
amyloid deposition results in interstitial expansion,
which can be visualized by typically patchy or subendo-
cardial LGE with early blood pool darkening on Look
Locker scout images. The characteristic diffuse LGE
enhancement though makes nulling of normal myocar-
dium particularly difficult, often leading to confusion in
interpretation [30].
T1 mapping circumvents the limitations of myocardial
nulling faced in LGE imaging, provides quantitative
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assessment of diffuse extracellular expansion, and is a vi-
able option in renal failure, which is common with amyl-
oid. Performed serially, it might be a means to follow
response to treatment and changes in myocardial burden
[31]. Both types of cardiac amyloidosis show markedly
elevated native T1 values (Figs. 2 and 5a). Using native
T1 cardiac amyloidosis could be reliably diagnosed and
differentiated from hypertrophic cardiomyopathy, a
clinically relevant differential diagnosis [32].
Cardiac amyloid is associated with a higher ECV than
any other cardiomyopathy (ECV 46.6 ± 7.0%) due to the
widespread and substantial extracellular infiltration [17].
Early detection of cardiac amyloidosis and differenti-
ation between the two main forms transthyretin-related
cardiac amyloidosis (ATTR) and light chains cardiac
amyloidosis (AL) is of high clinical importance because
untreated cardiac amyloidosis has poor prognosis. In
addition to supportive heart failure therapy, specific
treatment options are available for both ATTR (liver
transplantation, novel TTR-specific treatment) and AL
(chemotherapy, autologous stem cell transplantation)
[33]. Efforts to differentiate between ATTR and AL have
been made by Dungu et al., who reported higher LV
mass in patients with ATTR compared to AL and pro-
posed a sum LGE score (QALE score) for differential
diagnosis [34]: LGE patterns seem to be more extensive,
diffuse and transmural in ATTR (QALE score ≥13) and
more often showing a less extensive, more subendocar-
dial pattern in AL cardiac amyloidosis (QALE score <13)
[34]. The overlap between AL and ATTR amyloidosis,
Fig. 5 Multi-parametric tissue characterisation at mid-slice in diseases involving myocardium. On ECV-maps, red areas represent ECV greater than
30%. T1-mapping was done using a modified Look-Locker Inversion Recovery (MOLLI) pulse sequence on 1.5 Tesla Ingenia, Philips, Best, The
Netherlands. a Biopsy proven cardiac amyloidosis. T1 maps show diffuse rise in native-T1 values (a1). On LGE-imaging, there is low contrast-noise
ratio (CNR) between the blood pool and the myocardium (a2). ECV-maps demonstrate diffuse rise in extra-cellular space in the whole myocar-
dium. b Established rheumatoid arthritis demonstrating some rise in native T1 (b1) and ECV (b3) with normal signal distribution on LGE-imaging
(b2). c Established Systemic Sclerosis demonstrating rise in native T1 values predominantly in the septum (c1) and more widespread increase in
ECV (c3). There is no evidence of any scar or fibrosis on LGE-imaging. d Bio-chemical diagnosis of Fabry’s disease: Native T1 (e1) demonstrates
pseudo-normalization due to the effects of replacement fibrosis exceeding the fatty-related T1 decrease. LGE (e2) demonstrates fibrosis of the
lateral wall in consistence with the ECV map (e3). Abbreviations: ECV, extra-cellular volume; LGE, Late Gadolinium Enhancement
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though, remains substantial. Given the great therapeutic
consequence of ATTR (liver transplantation, novel TTR-
specific treatment) vs. AL amyloidosis (chemotherapy,
autologous stem cell transplantation) currently further
testing is required with cardiac biopsy, genetic testing,
or nuclear scanning to confidently distinguish between
the two disease types.
Nevertheless ECV has been proposed to become the
first non-invasive test to quantify cardiac amyloid bur-
den and could be used as a tool to guide and monitor
treatment [35].
Systemic cardiac disorders
Rheumatoid arthritis
Subclinical cardiovascular disease is common in patients
with rheumatoid arthritis (RA) and predominantly af-
fects young female subjects. Up to 39% of RA patients
have been reported to show focal LGE patterns, probably
related to earlier myocarditis [36]. However, diffuse fi-
brosis is common in RA and cannot be reliably detected
by LGE. In a pilot study, native T1 values were slightly
elevated in RA patients compared to controls and RA
patients had expanded ECV (30.3 ± 3.4 vs. 27.9 ± 2.0; p <
0.001) [37] (Figs. 2 and 5b). Disease activity scores corre-
lated with diffuse fibrosis and systolic and diastolic strain
regardless of LGE [37].
Systemic sclerosis
Cardiac involvement is common in systemic sclerosis, often
before cardiac symptoms occur. Low grade inflammation
and diffuse myocardial fibrosis are well-described co-
existing disease processes in systemic sclerosis and can be
detected by T2-STIR and LGE imaging. As in other dis-
eases, LGE is limited in the assessment of diffuse myocar-
dial fibrosis, especially when the entire myocardium may be
affected more homogeneously as occurs with systemic
sclerosis. In a small study, native T1 and ECV (35.4 ± 4.8 vs.
27.6 ± 2.5%) were elevated in patients with systemic scler-
osis (Figs. 2 and 5c) [38].
Anderson-fabry disease
Anderson-Fabry disease (AFD) is an intracellular lipid
disorder (lysosomal storage disease) that causes concen-
tric LV hypertrophy, heart failure and arrhythmias [39].
On LGE images, AFD typically displays an infero-
lateral mid-wall pattern of enhancement caused by focal
fibrosis in this region. In addition, the low native T1 of
fat can serve as an early surrogate marker of myocardial
glycosphingolipid storage in AFD even before the
development of LV hypertrophy [40]. Native T1 reliably
distinguished AFD from other common causes of LV
hypertrophy using a predefined cut-off [40]. However,
segmental T1 analysis in the infero-lateral wall showed
pseudo-normalized or even elevated T1 due to the
effects of replacement fibrosis exceeding the fatty-related
T1 decrease [40]. Unlike native T1, the ECV in AFD is
typically normal as AFD is an intracellular (lysosomal)
storage disease [17] and ECV values in AFD have been
reported to be similar to healthy controls (ECV 21.7 ±
3.0% [1.5T]) [41] (Figs. 2 and 5d).
Iron-overload cardiomyopathy
Iron-overload develops primarily from increased absorp-
tion such as in genetic hemochromatosis or secondary
to repeated blood transfusions, as in thalassaemia major
[42]. Cardiac iron deposition confers a poor prognosis
without (chelation) therapy [42]. Iron as a ferromagnetic
material is known to shorten the three fundamental tis-
sue MRI signal constants, T1, T2 and T2*. T2* currently
is the non-invasive gold standard method to quantify
iron deposition in myocardium [43]. Sado et al. have
shown shown that native T1 values were lower in pa-
tients with iron-overload cardiomyopathy with good cor-
relation with T2* [44] (Fig. 2). Compared with T2*
mapping, T1 has the advantage of higher reproduci-
bility, easier clinical use with less offline analysis
needed and the potential to detect early iron overload
[44]. On the other hand, unlike T2*, T1 is less patho-
logically specific and increased in various other car-
diomyopathies involving increased interstitial space
(fibrosis, amyloid). Therefore, early iron deposition
may be missed in these patients.
Diffuse fibrosis
Hypertrophic cardiomyopathy
Autosomal dominant mutations involving sarcomeric
genes lead to hypertrophic cardiomyopathy (HCM) and
a combination of myocyte disarray, fibrosis and ventricu-
lar hypertrophy in distinct patterns [45]. Clinically,
HCM is diagnosed by a combination of history (pedi-
gree), ECG signs and an evaluation of LV wall thickness.
LGE typically occurs at right ventricular (RV) insertion
points and with variable frequency and severity in hyper-
trophied, often hypocontractile segments [45]. Histologi-
cally, fibrosis is often more global, or diffuse, and often
undetectable by standard LGE pulse sequences (nulled
reference tissue potentially in area of diffuse fibrosis).
Native T1 values are prolonged in HCM and correlate
with wall thickness suggesting that it is a marker of dis-
ease severity [46, 47]. Patients with HCM have reduced
post-contrast myocardial T1 consistent with the pres-
ence of diffuse interstitial fibrosis outside areas of LGE.
ECV in HCM (29.1 ± 0.5% [1.5T]) [17] in segments with-
out LGE has shown to be in the upper normal range of
normal patients (Figs. 2 and 6a) [48]. ECV can be used
in the differential diagnosis of HCM vs. athletic remod-
elling in athlete’s heart, in particular in those subjects in
the grey zone of LV wall thickness (12–15 mm).
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Whereas ECV increases with increasing LV hypertrophy
in HCM (due to extracellular matrix expansion and
myocardial disarray), ECV reduces in athletes with in-
creasing wall thickness (due to an increase in healthy
myocardium by cellular hypertrophy) [48]. The impact
of myocardial disarray on T1 mapping in HCM, though,
remains controversial and may result in overestimation
of ECV [49].
Dilated cardiomyopathy
LV or biventricular dilatation and systolic dysfunction
without an obvious or detectable cause are the defining
characteristics of dilated (nonischaemic) cardiomyopathy
(DCM). In DCM, LGE typically occurs in a mid-wall
pattern [50] but in the majority of DCM there is lack of
any detectable LGE. Native T1 values are prolonged in
DCM and correlate with reduced wall thickness [46, 47].
ECV measurement reflects myocardial collagen content
in DCM and might serve as a non-invasive imaging bio-
marker to monitor therapy response and aid risk stratifi-
cation in different stages of DCM [51]. ECV in DCM
has been shown to be in a similar range to HCM (28 ±
0.4% [1.5T]) [17] (Figs. 2 and 6b). The pathophysiologic
correlates that are responsible for the similar ECV values
in DCM and HCM are not fully understood, but since
DCM and HCM can usually be distinguished by their
distinct ventricular geometry the overlap in ECV is clin-
ically irrelevant. Furthermore, ECV elevation is typically
pronounced in the mid-wall sections in DCM compared
with RV hinge points and hypertrophied segments in
HCM.
Heart failure and heart failure with preserved ejection
fraction
Heart failure is the final common pathway of many
cardiomyopathies. Myocardial fibrosis – regardless of
the aetiology – is a key mechanism in the development
of diastolic and systolic heart failure. Since collagen
deposition is often diffuse, LGE usually shows no
regional fibrosis/scarring. According to data from the
OPTIMIZE-HF registry preserved ejection fraction was
present in a large proportion of patients with heart
failure. Both heart failure patients with reduced and pre-
served ejection fraction experienced similar rates of
mortality and morbidity [52]. Su et al. have shown that
patients with systolic heart failure and heart failure with
preserved ejection fraction (HFpEF) had elevated ECV
in comparison with normal control subjects (31.2% vs.
Fig. 6 Multi-parametric tissue characterisation at mid-slice in cardiomyopathies. On ECV-maps, red areas represent ECV greater than 30%. T1-
mapping was done using a modified Look-Locker Inversion Recovery (MOLLI) pulse sequence on 1.5 Tesla Ingenia, Philips, Best, The Netherlands.
a HCM showing diffuse and heterogeneous LGE in the anterior wall (yellow arrow, a2). Native T1 was diffusely raised, exceeding the hypertrophied seg-
ments (a1). ECV-maps demonstrate higher ECV in and around the diffuse LGE (a3). b DCM with no LGE enhancement (b2) but raised native T1 values
in the septum (1000–1200ms) (b1) and raised ECV (b3). c HFpEF Native-T1 values were significantly raised through-out (>1000ms) with no presence of
scar on LGE-imaging (c2). ECV maps demonstrated patchy rise in extra-cellular space (c3). Abbreviations: DCM, dilated cardiomyopathy; ECV, extra-
cellular volume; HFpEF, heart failure with preserved ejection fraction; HCM, hypertrophic cardiomyopathy; LGE, Late Gadolinium Enhancement
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28.9% vs. 27.9%) [53] (Fig. 6c). ECV elevation thus might
help in identifying patients with worse prognosis other-
wise undetected by conventional LGE techniques.
Conclusions
Tissue characterisation by native T1 mapping may serve
as an important source of diagnostic, therapeutic and
prognostic decision making in various cardiac diseases.
An advantage of a non-invasive method for the assess-
ment of fibrosis is the potential to follow changes in the
myocardium over time as in patients with cardiomyopa-
thies or patients receiving cardiotoxic drugs. Patients
with poor renal function (or on dialysis) precluding
gadolinium-based contrast injection may benefit from
using native T1 mapping instead of LGE imaging. A clin-
ical scenario where multi-parametric CMR tissue charac-
terisation has already been established is in the
assessment of patients with acute chest pain and no cor-
onary artery disease. In such cases, tissue characterisa-
tion can assist in the differential diagnosis of micro-
infarction, (peri-) myocarditis and stress cardiomyopathy
(Takotsubo) and also other causes of diffuse fibrosis as-
sociated with high cardiac biomarker levels (such as
high-sensitivity cardiac troponin).
Clinically, several studies have shown that T1 mapping
with ECV is particularly useful in the assessment of car-
diac diseases with diffuse fibrosis. Furthermore, T1 map-
ping with ECV might be helpful as an adjunct in cases
with ambiguous LGE. Beyond differential diagnosis of
cardiomyopathies, tissue characterization with T1 map-
ping can be very useful in differentiating between pericar-
dial fat vs. LGE, differentiating between epicardial fat vs.
pericardial effusion as well as in tissue characterization of
various cardiac tumours.
More research is needed regarding the long-term
prognostic impact of T1/ECV mapping, as well as its po-
tential in therapy guidance of cardiac diseases such as
heart failure, patients after heart transplantation as well
as its role in valvular heart disease.
Harmonization of acquisition protocols between ven-
dors and institution will also be needed to allow wider
adoption of the methods.
Although tissue characterisation with native T1 and
ECV has been shown to have incremental diagnostic
benefit even in very early disease stages (e.g. diffuse
fibrosis not detectable by LGE), there is an overlap
between different cardiomyopathies and some overlap
with normal T1 values. Like all medical parameters,
abnormalities in native T1 and ECV need to be inter-
preted within their clinical context and pre-test prob-
abilities and in conjunction with established CMR
techniques such as LGE. Elevations and reductions of
T1 and ECV are not specific and can be caused by vari-
ous disease processes. In some instances, these processes
can even cancel each other out (e.g. pseudonormaliza-
tion in Anderson-Fabry disease when replacement fibro-
sis exceeds the fatty-related T1 decrease).
There is still some way to go with standardization of
T1 mapping methods and protocols. Ongoing research
for this purpose includes the use of standardized phan-
toms and software methods. For now, normal and
pathological T1 values will largely depend on the acqui-
sition scheme and will have to be defined in individual
CMR centres.
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